News You Can Use

Soared past 90% in VA system for low-risk disease, to 61% for favorable intermediate-risk disease

Alternative cancer clinics may market unvetted therapies and target vulnerable patients online.

More testing is needed, but the drug's unusual mechanism could open the door to a safer new treatment for advanced cancer.

Study findings suggest that the variant should be added to tests that identify cancer risks.

In this episode of Bench to Bedside and Beyond, we talk to a prostate cancer survivor and the medical director of Fred Hutch's cancer rehab about treatment's aftermath.

A negative scan does not always mean recurrent prostate cancer is nowhere to be found. Sometimes, the disease may simply be too small or too faint to appear yet.